In addition to its role in the sleep–wake cycle, melatonin inhibits tau phosphorylation (Deng et al., 2005) and reduces the release of APP from neurons (Lahiri, 1999), both hallmarks of AD. Here, MAPT is linked to Alzheimer disease.